An RNA Hybridization Assay for Screening Influenza A Virus Polymerase Inhibitors Using the Entire Ribonucleoprotein Complex

Assay and Drug Development Technologies

Volumn 13, Issue 8, 2015, Pages 488-506

  Roch, Franz Ferdinand ^a   Hinterkörner, Georg ^a   Menke, John ^b   Tang, Guo Qing ^b   Cusack, Stephen ^c   Butzendobler, Barbara ^a   Buschmann, Helmut ^a   Datta, Kausiki ^b   Wolkerstorfer, Andrea ^a  

^a Savira Pharmaceuticals GmbH   (Austria)

^b HOFFMANN LA ROCHE INC   (United States)

^c EUROPEAN MOLECULAR BIOLOGY LABORATORY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CAP BINDING INHIBITOR; CAP BINDING PROTEIN; EMBL R 05 1; EMBL R 05 2; EMBL R 05 3; ENDONUCLEASE; ENDONUCLEASE INHIBITOR; ENZYME INHIBITOR; FAVIPIRAVIR; FOLIC ACID; INFLUENZA A VIRUS POLYMERASE INHIBITOR; MONOSELECTIVE POLYMERASE INHIBITOR; NUCLEOZIN; RIBAVIRIN; RIBONUCLEOPROTEIN; RIBONUCLEOPROTEIN COMPLEX; RNA POLYMERASE; UNCLASSIFIED DRUG; VIRUS MESSENGER RNA; DNA DIRECTED RNA POLYMERASE;

ANALYTICAL EQUIPMENT; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ASSAY; FLUORESCENCE ANALYSIS; FLUORESCENCE QUENCHING ENDONUCLEASE ASSAY; GENETIC ANALYZER; HIGH THROUGHPUT SCREENING; IC50; INFLUENZA A VIRUS; NONHUMAN; PROCESS OPTIMIZATION; PROTEIN DOMAIN; RNA ANALYSIS; RNA HYBRIDIZATION; RNA HYBRIDIZATION ASSAY; SURFACE PLASMON RESONANCE; TRANSCRIPTION REGULATION; VIRUS REPLICATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; PHYSIOLOGY; PRECLINICAL STUDY; PROCEDURES;

ANTIVIRAL AGENTS; DNA-DIRECTED RNA POLYMERASES; DRUG EVALUATION, PRECLINICAL; HUMANS; INFLUENZA A VIRUS; RIBONUCLEOPROTEINS; VIRUS REPLICATION;

EID: 84944452242     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2015.668     Document Type: Article

References (51)

1. WHO: Influenza fact sheet. 2014. www.who.int/mediaeentre/faetsheets/fs211/en/. (Last accessed on March 9, 2015).
2. Jagger BW, Wise HM, Kash JC, et al.: An overlapping protein-coding region in influenza A virus segment 3 modulates the host response. Science 2012;337:199-204.
3. Wise HM, Foeglein A, Sun J, et al: A complicated message: identification of a novel PB1-related protein translated from influenza A virus segment 2 mRNA. J Virol 2009;83:8021-8031.
4. Das K: Antivirals targeting influenza A virus. J Med Chem 2012;55:6263-6277.
5. Boivin S, Cusaek S, Ruigrok RW, Hart DJ: Influenza virus polymerase: structural insights into replication and host adaptation mechanisms. J Biol Chem 2010; 285:28411-28417.
6. Martin-Benito J, Ortin J: Influenza virus transcription and replication. Adv Virus Res 2013;87:113-137.
7. Fodor E: The RNA polymerase of influenza a virus: mechanisms of viral transcription and replication. Acta Wro/2013;57:113-122.
8. Hastings JC, Selniek H, Wolanski B, Tomassin JE: Anti-influenza virus activities of 4-substituted 2, 4-dioxobutanoie acid inhibitors. Antimicrob Agents Chemother 1996;40:1304-1307.
9. Tomassini J, Selniek H, Davies ME, et al: Inhibition of cap (m7GpppXm)-dependent endonuelease of influenza virus by 4-substituted 2, 4-dioxobutanoie acid compounds. Antimicrob Agents Chemother 1994;38:2827-2837.
10. Tomassini JE, Davies ME, Hastings JC, et al: A novel antiviral agent which inhibits the endonuelease of influenza viruses. Antimicrob Agents Chemother 1996;40:1189-1193.
11. Parkes KEB, Ermert P, Fuhssler J, et al: Use of a pharmacophore model to discover a new class of influenza endonuelease inhibitors. J Med Chem 2003;46:1153-1164.
12. Hooker L, Sully RR, Handa B, Ono N, Koyano H, Klumpp K: Quantitative analysis of influenza virus RNP interaction with RNA cap structures and comparison to human cap binding protein elF4E. Biochemistry 2003;42: 6234-6240.
13. Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG: Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003;326:1235.
14. Hayden FG, de Jong MD: Emerging influenza antiviral resistance threats. J Infect Dis 2011;203:6-10.
15. Hayden F: Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 2009;48:3-13.
16. Arranz R, Coloma R, Chichon FJ, et al: The structure of native influenza virion ribonucleoproteins. Science 2012;338:1634-1637.
17. Moeller A, Kirchdoerfer RN, Potter CS, Carragher B, Wilson IA: Organization of the influenza virus replication machinery. Science 2012;338:1631-1634.
18. Dias A, Bouvier D, Crepin T, et al.: The cap-snatching endonuelease of influenza virus polymerase resides in the PA subunit. Nature 2009;458:914-918.
19. He X, Zhou J, Bartlam M, et al: Crystal structure of the polymerase PA-C-PB1-N complex from an avian influenza H5N1 virus. Nature 2008;454:1123-1126.
20. Sugiyama K, Obayashi E, Kawaguchi A, et al: Structural insight into the essential PB1-PB2 subunit contact of the influenza virus RNA polymerase. EMBO Journal 2009;28:1803-1811.
21. Guilligay D, Tarendeau F, Resa-lnfante P:The structural basis for cap binding by influenza virus polymerase subunit PB2. Chemtracts 2008;20:509-510.
22. Tarendeau F, Crepin T, Guilligay D, Ruigrok RWH, Cusaek S, Hart DJ: Host determinant residue lysine 627 lies on the surface of a discrete, folded domain of influenza virus polymerase PB2 subunit. PioS Pathog 2008;4; e1000136.
23. Pflug A, Guilligay D, Reich S, Cusaek S: Structure of influenza A polymerase bound to the viral RNA promoter. Nature 2014;516:355-360.
24. Reich S, Guilligay D, Pflug A, et al: Structural insight into cap-snatching and RNA synthesis by influenza polymerase. Nature 2014;516:361-366.
25. Dubois RM, Slavish PJ, Baughman BM, et al: Structural and biochemical basis for development of influenza virus inhibitors targeting the PA endonuelease. PioS Pathog 2012;8:e1002830.
26. Parhi AK, Xiang A, Bauman JD, et al: Phenyl substituted 3-hydroxypyridin-2(1H)-ones: inhibitors of influenza A endonuelease. Bioorg Med Chem 2013;21: 6435-6446.
27. Kowalinski E, Zubieta C, Wolkerstorfer A, Szolar OH, Ruigrok RW, Cusack S: Structural analysis of specific metal chelating inhibitor binding totheendonuclease domain of influenza pHINI (2009) polymerase. P/-oSPoftog2012;8:e1002831.
28. Lv HM, Guo XL, Gu RX, Wei DQ: Free energy calculations and binding analysis of two potential anti-influenza drugs with Polymerase basic protein-2 (PB2). Protein Pept Lett 2011 ;18:1002-1009.
29. Pautus S, Sehr P, Lewis J, ef at New 7-methylguanine derivatives targeting the influenza polymerase PB2 cap-binding domain. J Med Chem 2013;56:8915-8930.
30. Panomics: QuantiGene 2.0 Gene Expression without the Limitations. Affymetrix/Panomics Brochure. 2007. www.panomics.com/products/gene-expression/single-plex-assay/literature-support (Last accessed on March 9, 2015).
31. Guilligay D, Tarendeau F, Resa-lnfante P, et al: The structural basis for cap binding by influenza virus polymerase subunit PB2. Nat Struct Mol Biol 2008; 15:500-506.
32. Nikolovska-Coleska Z, Wang R, Fang X, et al Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization. Anal Biochem 2004;332:261-273.
33. Baughman BM, Jake SP, Dubois RM, Boyd VA, White SW, Webb TR: Identification of influenza endonuclease inhibitors using a novel fluorescence polarization assay. ACS Chem Biol 2012;7:526-534.
34. Klumpp K, Hooker L, Handa B: Influenza virus endoribonuclease. Methods Enzymol 2001;342:451-466.
35. Panomics: QuantiGene 2.0 Reagent System. User Manual. 2007. www.panomics.com/downloads/UM13074-QG2Manual-RevB-080102.pdf. (Last accessed on March 9, 2015).
36. Datta K, Wolkerstorfer A, Szolar OH, Cusack S, Klumpp K: Characterization of PA-N terminal domain of influenza A polymerase reveals sequence specific RNA cleavage. Nucleic Acids Res 2013;41:8289-8299.
37. Reed U, Muench H: A simple method of estimating fifty per cent end points. Am J Epidemiol 1938;27:493-497.
38. Deng T, Vreede FT, Brownlee GG. Different de novo initiation strategies are used by influenza virus RNA polymerase on its cRNA and viral RNA promoters during viral RNA replication. J Virol 2006;80:2337-2348.
39. Kawakami K, Mizumoto K, Ishihama A, Shinozaki-Yamaguchi K, Miura K: Activation of influenza virus-associated RNA polymerase by cap-1 structure (m7GpppNm). J Biochem 1985;97:655-661.
40. Doan L, Handa B, Roberts NA, Klumpp K: Metal ion catalysis of RNA cleavage by the influenza virus endonuclease. Biochemistry 1999;38:5612-5619.
41. Crepin T, Dias A, Palencia A, Swale C, Cusack S, Ruigrok RW: Mutational and metal binding analysis of the endonuclease domain of the influenza virus polymerase PA subunit. J Virol 2010;84:9096-9104.
42. Kao RY, Yang D, Lau LS, et al:. Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol 2010;28:600-605.
43. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1, 2, 4-triazole-3-carboxamide. Science 1972;177:705-706.
44. Snell NJ.: Ribavirin-current status of a broad spectrum antiviral agent. Expert Opin Pharmacother 2001;2:1317-1324.
45. Furuta Y. Takahashi K, Fukuda Y, et al:. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 2002;46:977-981.
46. Furuta Y, Takahashi K, Shiraki K, et al: T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 2009;82:95-102.
47. Crotty S, Cameron C, Andino R.: Ribavirin's antiviral mechanism of action: lethal mutagenesis? J Mol Med (Berlj 2002;80:86-95.
48. Cameron CE, Castro C: The mechanism of action of ribavirin: lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase. Curr Opin Infect Dis 2001;14:757-764.
49. Kentsis A, Topisirovic I, Culjkovic B, Shao L, Borden KLB.: Ribavirin suppresses elF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sei USA 2004;101:18105-18110.
50. Matsuo H, Li H, McGuire AM, et al. Structure of translation factor elF4E bound to m7GDP and interaction with 4E-binding protein. Nat Struct Biol 1997;4:717-724.
51. Yan Y, Svitkin Y, Lee JM, Bisaillon M, Pelletier J.: Ribavirin is not a functional mimic of the 7-methyl guanosine mRNA cap. RNA 2005;11:1238-1244.